At a time when self-insurance employers are on the lookout for methods to deal with rising healthcare prices, the rise of GLP-1 weight reduction medicines poses some attention-grabbing questions for employers. Can investing in these costly medicine as a well being profit cut back the prices of power circumstances in the long run? How do employers resolve who ought to have entry to those medicines, which have been initially developed for sort 2 diabetes? How can employers be assured that staff will develop wholesome habits, comparable to altering weight loss program and train routines, so that they get a return on their funding?

In a dialog with Arundhati Parmar, editor-in-chief of MedCity Information, Jeff Jacques, Chief Medical Officer of Personify Well being, talks in regards to the various kinds of GLP-1 medicines, what share of employers presently supply the medicines, and what number of employers are contemplating sharing them to do away with the medicines. of their well being advantages sooner or later.